Endocrine Abstracts

Objective: Flash glucose monitoring (FGM) facilitates non-invasive glucose level assessment. Since November 2020 this system is subsidized in patients with type 3c diabetes (DM3c) Our objective was to describe the characteristics of these patients and their glycemic control expressed as times in range.

Methods and patients: Observational longitudinal clinical study between January 2021 and January 2023 in patients with DM3c.

Results: 68 patients included. Mean age: 62.17 ± 10.43 years, with DM diagnosed with a mean age of 52.21 ± 13.02 years. 29.4% women. Mean BMI 25.33 ± 4.65 kg/m². 72.1% use of pancreatic enzymes in these patients. Total insulin dose 0.50± 0.32 UI/kg. 14.7% patients not using prandial insulin. DM3c etiology: 33.8% Chronic pancreatitis 61.8% Pancreatic surgery 4.4% Cystic fibrosis FGM metrics: A median use of 92.00% (with 85% use as 25^th percentile). 10.26 ± 4.74% daily scans. 68.07 ± 19.57% time in range, 21.24 ± 11.34% time between 180-250 mg/dl, 8.47 ± 11.95% time above 250 mg/dl, 2.47 ± 1.00% time between 54-70 mg/dl, 0.28 ± 1.17% time below 54 mg/dl. Glycemic CV 32.89 ± 7.89%. 39.1%. GMI 7.07 ± 0.76%.

Conclusion: - The main cause of DM3c in our series was surgical pancreatic resection (61.8% of patients). Almost three quarters of them had also exocrine insufficiency.- In our series of patients with DM3c, glycemic control was suboptimal due to hyperglycemia. Glycemic variation was adequate and hypoglycemia targets were met.